# Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises

> **NCT02573714** · NA · UNKNOWN · sponsor: **Cameroon Baptist Convention Health** · enrollment: 160 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Normal Saline
- **OTHER:** Standard Pain Therapy
- **OTHER:** Pediatric Quality of Life - Sickle Cell Disease Module
- **OTHER:** Faces Pain Scale - Revised

## Key facts

- **NCT ID:** NCT02573714
- **Lead sponsor:** Cameroon Baptist Convention Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573714, "Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02573714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*